Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings

[1] Wade A(2017)A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy Aust Fam Physician 46 235-240

[2] Draper B(2011)General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting Aust J Prim Health 17 282-287

[3] Doyle J(2011)Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia J Viral Hepatitis 18 e104-ee16

[4] Allard N(2018)Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One 13 2199-2207

[5] Grinzi P(2011)Outcomes of treatment for hepatitis C virus infection by primary care providers N Engl J Med 364 432-438

[6] Thompson A(2017)Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs Am J Med 130 3620-3625

[7] Lambert SM(2013)Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in northern California Dig Dis Sci 58 432-453

[8] Page AN(2019)Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review Journal of Viral Hepatitis 26 1089-1098

[9] Wittmann J(2018)Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C J Viral Hepat 25 311-318

[10] Hayllar JS(2017)Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers a nonrandomized clinical trial Ann Intern Med 167 209-215

[1] Wade A(2017)A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy Aust Fam Physician 46 235-240

[2] Draper B(2011)General practitioner attitudes to prescribing hepatitis C antiviral therapy in a community setting Aust J Prim Health 17 282-287

[3] Doyle J(2011)Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia J Viral Hepatitis 18 e104-ee16

[4] Allard N(2018)Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One 13 2199-2207

[5] Grinzi P(2011)Outcomes of treatment for hepatitis C virus infection by primary care providers N Engl J Med 364 432-438

[6] Thompson A(2017)Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the Department of Veterans Affairs Am J Med 130 3620-3625

[7] Lambert SM(2013)Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in northern California Dig Dis Sci 58 432-453

[8] Page AN(2019)Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review Journal of Viral Hepatitis 26 1089-1098

[9] Wittmann J(2018)Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C J Viral Hepat 25 311-318

[10] Hayllar JS(2017)Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers a nonrandomized clinical trial Ann Intern Med 167 209-215